Market Overview

UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

Share:
Related IMGN
Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough'
Here's Why Oppenheimer Upgraded ImmunoGen To Outperform

Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN) from Outperform to Perform and maintained a $14.00 price target.

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to IMGN901 and will watch the NORTH study as it will likely be the next driver of IMGN that could move us off the sidelines. A NORTH update is expected 2H13. With the launch of T-DM1, as with any drug launch, initial Street expectations may be adjusted. A post-launch pullback in IMGN into low teens may also cause us to revisit our rating."

ImmunoGen closed at $15.04 on Friday.

Latest Ratings for IMGN

DateFirmActionFromTo
Feb 2015OppenheimerUpgradesMarket PerformOutperform
Dec 2014JP MorganMaintainsNeutral
Dec 2014Leerink Swann

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (IMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→